Recent changes
L'OREAL UV Absorbing Composition with Physical Filters and Three Emollients
USPTO published L'OREAL's patent application (US20260096966A1) for a UV-absorbing composition combining at least one physical UV-attenuating material with an emollient system containing at least three emollients. The invention includes methods of making and using such compositions for topical applications. The application was filed on October 3, 2025, under Application No. 19349244.
UV Absorbing System With Physical Material Coloring Agent
USPTO published L'OREAL's patent application (US20260096967A1) for UV-absorbing compositions containing physical UV-attenuating materials and coloring agents. The application covers methods of making and using such cosmetic compositions for sun protection. The application was filed October 3, 2025.
Active Premix Aluminum Zirconium Salts Antiperspirant
USPTO published patent application US20260096968A1 by Wade Charles Henke, Shawn David McConaughy, and David Frederick Swaile covering a particulate active premix composition containing an aluminum zirconium salt, an amino acid, and greater than 1% of an alkali metal salt for use in antiperspirant products.
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Glutathione Trisulfide Patent for Chemotherapy-Induced Neuropathy
Pharmaceutical Composition Containing Mitochondria-Targeting Compound for Treating Macular Degeneration
The USPTO published patent application US20260097092A1 filed by Ulsan National Institute of Science and Technology for a pharmaceutical composition containing mitochondria-targeting compounds as active ingredients for treating macular degeneration and other retinal diseases. The application specifically covers compounds that induce apoptosis of senescent cells for prevention and treatment of aging-related diseases. The application was originally filed on January 11, 2023.
Targeted Amatoxin Conjugate for Treatment of Solid Tumors
Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.
DBI Protein Modulation Methods for Autophagy and Metabolic Regulation
The USPTO published patent application US20260097094A1 disclosing methods for modulating diazepam binding inhibitor (DBI) protein activity to regulate autophagy and metabolic processes. The inventors demonstrate that DBI neutralization via monoclonal antibodies or active immunization induces autophagy, enhances starvation-induced weight loss, reduces food intake upon refeeding, and reduces weight gain from hypercaloric diets. The patent covers pharmaceutical compositions and therapeutic applications for metabolic disorders.
Pegylated Lipoprotein Nanoparticles Treat Neurodegenerative Diseases
The USPTO published patent application US20260097095A1 for pegylated reconstituted high-density lipoprotein nanoparticles designed to prevent or treat neurodegenerative diseases. The application, filed by inventors Lee, Kim, and Kim on October 10, 2025, was published on April 9, 2026.
4-1BBL AND IL-12 COMBINATION THERAPY FOR GLIOBLASTOMA
The USPTO published patent application US20260097096A1, a new intellectual property grant covering methods of treating glioblastoma using 4-1BBL administered via adeno-associated virus (AAV-F) in combination with recombinant IL-12 delivered by intratumoral injection. The patent names Koen Breyne, Xandra O. Breakefield, and Thorsten R. Mempel as inventors. Biotech and pharmaceutical companies developing cancer immunotherapies must monitor this IP landscape.
Painless NGF Compositions for Fracture Repair
The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
693 changes in last 7 days
Latest high priority updates
140 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.